regenicin page header biomedical collagen polymer header
 
 

Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.


 

Regenicin is playing a critical role in the development of the therapeutic candidate, NovaDerm™, a cultured cell technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.

 
show stock information

November 17, 2016: Regenicin Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm®. click to read artictle
 
November 1, 2016: Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm® . click to read artictle
 
October 12, 2016: Regenicin, Inc. Announces Pre-IND Meeting with U.S. Food and Drug Administration (FDA) for its New NovaDerm® . click to read artictle
 
October 5, 2016: Regenicin Conducts an Evaluation of its Proprietary Collagen-Based Scaffold for Use in New Autologous Cultured Skin Substitute. click to read artictle
 
August 29, 2016: FDA Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute

click to read artictle This takes you to the article on the PR Newswire website. Click the Home button on the top menu to return.
 
February 9, 2016: Regenicin Reports 2015 Operating Results, Outlines Milestones for Q1 2016
click to read artictle This takes you to the article on the PR Newswire website. Click the Home button on the top menu to return.